TORADOL 10 MG
KETOROLAC TROMETHAMINE : 10 MG · DIN 02162660 · AA PHARMA INC
Health Canada status: MARKETED
What is TORADOL?
TORADOL 10 MG contains KETOROLAC TROMETHAMINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02162660, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TORADOL used for?
Short-term management of moderate to moderately severe acute pain, including post-surgical, acute musculoskeletal trauma, and post-partum uterine cramping pain. Not to exceed 5-7 days.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02162660 |
|---|---|
| Brand name | TORADOL |
| Generic / active ingredient | KETOROLAC TROMETHAMINE : 10 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AB15 KETOROLAC |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 30-Jul-2018 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Usual dose: 10 mg every 4-6 hours as required. Max 40 mg/day. Max duration: 5 days for post-surgical pain, 7 days for musculoskeletal pain. Take with meals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned but content not visible), though standard House Standard applies.
How is it supplied?
Bottles of 100 tablets.
Contraindications
Hypersensitivity to ketorolac or NSAIDs; CABG surgery; 3rd trimester pregnancy; labour/delivery; breastfeeding; severe HF; active peptic ulcer/GI bleed; inflammatory bowel disease; coagulation disorders.
Warnings and precautions
Serious CV risk (MI, stroke); Serious GI risk (bleeding, ulceration, perforation); Risk of fluid retention and edema; Renal effects; Inhibits platelet function.
Is KETOROLAC in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by AA PHARMA INC (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code M01AB15 KETOROLAC. 8 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-KETOROLAC | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02229080 |
| JAMP KETOROLAC | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02510855 |
| KETOROLAC TROMETHAMINE INJECTION, USP | 30 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02443376 |
| KETOROLAC TROMETHAMINE INJECTION, USP | 30 MG | LIQUID | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02244947 |
| MAR-KETOROLAC | 10 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02465124 |
| MINT-KETOROLAC | 10 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02461455 |
| TORADOL IM | 10 MG | SOLUTION | ATNAHS PHARMA UK LIMITED | MARKETED | DIN 02162644 |
| APO-KETOROLAC INJECTABLE | 30 MG | SOLUTION | APOTEX INC | DORMANT | DIN 02243989 |
| KETOROLAC TROMETHAMINE INJECTION USP | 10 MG | LIQUID | SABEX INC | CANCELLED PRE MARKET | DIN 02239943 |
| KETOROLAC TROMETHAMINE INJECTION USP | 30 MG | SOLUTION | STERIMAX INC | APPROVED | DIN 02461129 |
Who else supplies KETOROLAC worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. KETOROLAC appears in 48 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.